Biosimilar vs originator insulins: Systematic review and meta‐analysis-Reference-Cited by-同舟云学术

Biosimilar vs originator insulins: Systematic review and meta‐analysis

Published:2018-04-17 Issue:7 Volume:20 Page:1787-1792
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Yamada Tomohide¹^ORCID,Kamata Ryuichi¹,Ishinohachi Kotomi¹,Shojima Nobuhiro¹,Ananiadou Sophia²,Nom Hisashi³,Yamauchi Toshimasa¹,Kadowaki Takashi¹

Affiliation:

1. Department of Diabetes and Metabolic Diseases, Graduate School of Medicine University of Tokyo Tokyo Japan

2. National Centre for Text Mining, School of Computer Science University of Manchester Manchester UK

3. Department of Data Science Institute of Statistical Mathematics Tokyo Japan

Funder

Japan Society for the Promotion of Science

Japan Foundation for Applied Enzymology

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.13291

Reference22 articles.

1. Essential medicines for universal health coverage

2. Introduction of biosimilar insulins in Europe

3. Constraints and challenges in access to insulin: a global perspective

4. Generics and Biosimilar Initiative: Biosimilars of insulin glargine.http://gabionline.net/Biosimilars/General/Biosimilars‐of‐insulin‐glargine. Accessed March 20 2018.

5. Food and Drug Administration.Guidance for industry: scientific considerations in demonstrating Interchangeability with a Reference Product.2017.https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM537135.pdf. Accessed December 16 2017.

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapy of Type 2 Diabetes;Experimental and Clinical Endocrinology & Diabetes;2024-04-10

2. Therapie des Typ-2-Diabetes;Die Diabetologie;2024-01-30

3. Treatment of type 2 diabetes;Die Diabetologie;2023-04-27

4. An Institutional Guide for Formulary Decisions of Biosimilars;Hospital Pharmacy;2022-11-29

5. Therapy of Type 2 Diabetes;Experimental and Clinical Endocrinology & Diabetes;2022-07-15